Fiercebiotech
Published November 16, 2026
Helus' chemically modified psychedelic hits key goals in phase 3 depression trial
Read the full story at Fiercebiotech
There were no serious adverse events seen in the placebo arm, the company noted. The psychedelics sector, in general, has seen renewed energy this.
Surfaced by this Google Alert
- Psychedelics